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Subtle mood fluctuations are normal emotional experiences, whereas drastic mood swings can be a manifestation of bipolar disorder
(BPD). Despite their importance for normal and pathological behavior, the mechanisms underlying endogenous mood instability are
largely unknown. During embryogenesis, the transcription factor Otx2 orchestrates the genetic networks directing the specification of
dopaminergic (DA) and serotonergic (5-HT) neurons. Here we behaviorally phenotyped mouse mutants overexpressing Otx2 in the
hindbrain, resulting in an increased number of DA neurons and a decreased number of 5-HT neurons in both developing and mature
animals. Over the course of 1 month, control animals exhibited stable locomotor activity in their home cages, whereas mutants showed
extended periods of elevated or decreased activity relative to their individual average. Additional behavioral paradigms, testing for manic- and
depressive-like behavior, demonstrated that mutants showed an increase in intra-individual fluctuations in locomotor activity, habituation, risk-
taking behavioral parameters, social interaction, and hedonic-like behavior. Olanzapine, lithium, and carbamazepine ameliorated the behavioral
alterations of the mutants, as did the mixed serotonin receptor agonist quipazine and the specific 5-HT2C receptor agonist CP-809101.
Testing the relevance of the genetic networks specifying monoaminergic neurons for BPD in humans, we applied an interval-based
enrichment analysis tool for genome-wide association studies. We observed that the genes specifying DA and 5-HT neurons exhibit a
significant level of aggregated association with BPD but not with schizophrenia or major depressive disorder. The results of our translational
study suggest that aberrant development of monoaminergic neurons leads to mood fluctuations and may be associated with BPD.





















































Subtle mood swings are normal experiences of healthy
individuals, whereas extreme mood swings are a hallmark
of bipolar disorder (BPD; Belmaker, 2004). There is a
substantial genetic contribution to the risk of BPD that does
not follow any of the simple mendelian patterns of
inheritance. On the basis of genome-wide association
studies (GWAS), various individual susceptibility genes
for BPD have been suggested (Craddock and Sklar, 2013),
although the specific molecular pathways in which these
genes operate in BPD are not known. Recently developed
pathway-based GWAS analysis tools have enabled identifi-
cation of genetic variants of groups of genes that interact in
a particular biological process and that have a significant
joint effect on BPD (Lee et al, 2012; Wang et al, 2007). In
these studies, genes critical for neural development were
identified, including members of the Wnt signaling pathway
(Pandey et al, 2012; Pedroso et al, 2012; Zandi et al, 2008).
A key challenge remaining is the translation of established
genetic associations into a better pathophysiological under-
standing of BPD.
The difficulties to model the complex symptomatology of
BPD in animals have been a major obstacle for investigating
the neurobiology of this condition. Although different
models mimic manic- or depressive-like behavior (Dao
et al, 2010; Engel et al, 2009; Han et al, 2013; Roybal et al,
2007; Shaltiel et al, 2008), few animal paradigms provide
insights into the major characteristics of BPD, emotional
lability, and behavioral fluctuations. Overexpressing
glucocorticoid receptors in the forebrain of mice leads to
depressive-like behavior, supersensitivity to antidepres-
sants, and enhanced sensitization for cocaine, indicating
that emotional lability can be caused by aberrant gluco-
corticoid signaling (Wei et al, 2004). Neuron-specific
accumulation of mitochondrial DNA mutations leads to
estrous cycle-dependent periodic changes in locomotor
activity patterns in females, which are reversed by
ovariectomy or exposure to chronic lithium (Kasahara
et al, 2006). In male mice, these mitochondrial changes do
not lead to behavioral fluctuations. However, spontaneous
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fluctuations in manic- and depressive-like behavior have
not been modeled (Chen et al, 2010; Kara and Einat, 2013;
Nestler and Hyman, 2010).
On the basis of suggested mechanisms of action of BPD
medications, a complex imbalance of dopamine and serotonin,
here referred to as monoamines, is thought to have a critical
role in this condition (Beaulieu, 2012; Lesch and Waider,
2012). Although different lines of evidence have suggested the
importance of neurodevelopmental alterations in BPD (Ayhan
et al, 2011; Sanches et al, 2008), a role for monoaminergic
neuron development in mood instability and BPD has not
previously been described. The major dopaminergic (DA) and
serotonergic (5-HT) neuronal populations develop as neigh-
boring cell groups at the embryonic mid–hindbrain junction.
The DA neurons form in the midbrain and the 5-HT neurons
originate adjacently in the hindbrain (Brodski et al, 2003). We
previously reported that the transcription factor Otx2, together
with Wnts and their signaling molecules, regulate genetic
pathways controlling the specification of monoaminergic
neurons. Otx2, expressed in the midbrain with a sharp boun-
7dary to the hindbrain, induces the formation of DA neurons
and represses generation of 5-HT neurons (Brodski et al, 2003;
Omodei et al, 2008; Prakash et al, 2006). Interestingly, Otx2 as
well as Wnt pathway members have been proposed as
susceptibility genes for BPD (Pandey et al, 2012; Pedroso
et al, 2012; Sabunciyan et al, 2007; Zandi et al, 2008).
Mouse mutants expressing Otx2 under the endogenous
promoter of En1, active in a strip on either side of the
mid–hindbrain junction, ectopically express Otx2 in the
hindbrain (En1þ /Otx2). These changes result in an increase
in the number of specified DA neurons and a complemen-
tary reduction in the number of specified 5-HT neurons.
Despite changes in cell numbers, monoaminergic neurons
migrate and project normally in these animals (Brodski
et al, 2003). Transmitter measurements, transporter binding
assays, and autoradiography all indicate a subtle increase in
striatal DA innervation and a marked general decrease of
5-HT innervation in adult mutants (Brodski et al, 2003;
Tilleman et al, 2009). Behaviorally, En1þ /Otx2 mutants
are hyperactive and exhibit more stereotyped behavior
(Tilleman et al, 2009), as do amphetamine-treated wild-type
mice, a predominant model for one domain of manic-like
behavior (Chen et al, 2010; Gould et al, 2007; Kara and
Einat, 2013; Nestler and Hyman, 2010).
In this study, we employed En1þ /Otx2 mutants to investi-
gate how aberrant development of monoaminergic neurons
results in manic- and depressive-like behavior. These
animals are particularly well suited to address this question
due to their well-characterized changes in monoaminergic
neurons, in both developing and mature animals. In addi-
tion, we describe here our application of a pathway
enrichment tool for GWAS (Lee et al, 2012) to test the
relevance of our preclinical findings for BPD in humans.
MATERIALS AND METHODS
Animals
As a control for En1þ /Otx2 mutants, wild-type littermates
(WT) were used. All behavioral experiments were performed
on 3- to 6-month-old males, previously single caged for
at least 1 week. The apparatus, animal handling, and working
protocols are described in detail in the Supplementary
Methods. All procedures and experiments with the animals
were conducted in accordance with Ethics Committee
approval IL-13-03-2010, BGU.
Pharmacological Treatment
Lithium and carbamazepine were mixed in food, whereas olan-
zapine, quipazine, and CP-809,101 were administered to the
animals by 10ml/kg IP injections. Treatment, doses, and pro-
tocols are described in detail in the Supplementary Methods.
Behavioral Tests
Behavioral tests are described in detail in the Supple-
mentary Methods.
Statistical Analysis
All results are expressed as mean±SE. A two-tailed
unpaired Student’s t-test, two-way multifactorial analysis
of variance (ANOVA test), Fisher’s LSD post hoc analysis,
and false discovery rate (FDR) were used and described in
the Supplementary Methods.
INRICH Pathway Analysis
We used the interval-based pathway analysis software
(INRICH) as previously described (Lee et al, 2012). The
parameters used for the analysis are described in detail in
the Supplementary Methods.
RESULTS
En1þ /Otx2 Mutants Show Extended Periods of Increased
or Reduced Activity Relative to their Individual Average
First, we studied the activity of En1þ /Otx2 mutants in their
home cage, using surgically implanted telemetry activity
probes, during a normal light–dark cycle of 12 h. Individual
WT animals maintained a similar level of locomotor activity
throughout the observed 30-day period (Figure 1a). In
contrast, En1þ /Otx2 mutants exhibited extended periods of
increased and decreased activity, each animal compared
with its individual average activity level (Figure 1b).
Fluctuations were quantified by assessing the coefficient
of variation (CV), calculated by dividing the SD of the mean
activity of each individual animal by its mean activity
(Lucki et al, 2001; Fontana et al, 2014). Mutants showed a
significantly higher CV compared with controls (Figure 1c).
Increased CV for mutants was also observed under
conditions of constant darkness (Supplementary Figure 1).
En1þ /Otx2 mutants were hyperactive during the dark phase
and showed increased vigilance at the beginning and end of
the light phase (Figure 1d). Taken together, En1þ /Otx2
mutants show increased intra-individual changes in their
spontaneous activity levels over time.
En1þ /Otx2 Mutants Exhibit Increased Intra-Individual
Fluctuation in Activity, Habituation, Risk-Taking
Behavior, Sociability, and Hedonic-Like Behavior
To further study behavioral fluctuations of En1þ /Otx2
mutants, we repetitively exposed animals to the open-field
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test (OFT). We assessed locomotor activity as well as risk-
taking behavior in WT and En1þ /Otx2 mutants by measur-
ing the ratio (center vs total) of distance traveled as well
as the number of entries into the center of the OFT. CVs
for locomotor activity and risk-taking parameters were
increased in the En1þ /Otx2 mice compared with controls
(Figure 2a–c). Mutants were more active and entered into
the center more than controls, while the percentage of the
distance traveled in the center did not significantly differ
between the genotypes (Supplementary Figure 2a). The
activity was correlated with the risk-taking behavior in
mutants stronger than in controls and it was not corre-
lated with the CV for both the mutants and the con-
trols (Supplementary Figure 3a and c). We then quantified
intra-session habituation of En1þ /Otx2 mutants using the
activity change ratio (ACR; see Supplementary Methods).
The CV for ACRs of the mutant mice was significantly
increased (Figure 2d). WTs consistently had ACRs below
50%, indicating that they habituate during the OFT session.
In contrast, the most active En1þ /Otx2 mutants had ACRs of
50% or more, indicating that they either failed to habituate
or increased locomotion (Supplementary Figure 3b).
Social interaction test was used in the OFT to compare
variations in sociability of mutants and WT mice. En1þ /Otx2
mutants showed an increased CV for the time they engaged
in social interaction (Figure 2e), whereas the time they spent
in social interaction was decreased compared with the WTs
(Supplementary Figure 2b).
To study hedonic-like behavior, we employed the sucrose
preference test. Both WTs and mutants demonstrated
sucrose preference for a 2 and 5% solution. However, the
sucrose preference in the mutant mice was lower compared
with WTs (Supplementary Figure 2c). Their CV was
increased for sucrose preference and sucrose intake, but
not for total liquid intake compared with controls for the
2% (Figure 2f–h) and the 5% sucrose concentration
(t18¼ 3.458, p¼ 0.003; t18¼ 3.029, p¼ 0.001; t18¼ 3.029,
p¼ 0.108). Taken together, En1þ /Otx2 mutants show a
mixed state of manic- and depressive-like behaviors, fluc-
tuating over time.
En1þ /Otx2 Mutants Show Increased Manic-Like Behavior
that can be Ameliorated by Acute Olanzapine Treatment
Anxiety-like/risk-taking behavior was studied in the ele-
vated plus maze (EPM) and light–dark box (LDB). As these
tests cannot be repetitively applied without diminishing
validity, each animal was exposed to them only once.
En1þ /Otx2 mice showed consistently decreased anxiety-like
behavior/increased risk-taking behavior. In the EPM, mutants
exhibited proportional (open arm vs all arms) increase in
open-arm entries and duration (Supplementary Figure 2d).
Mutants also spent more time in the light compartment of
the LDB (Supplementary Figure 2e).
We then tested whether olanzapine exposure, used as an
acute treatment for mania, can improve behavioral altera-
tions of En1þ /Otx2 mutants. Acute olanzapine treatment
selectively reduced the percentage of entries into open arms
for En1þ /Otx2 mutants, but not for WT mice (Figure 3a).
There was no interaction between genotype and treatment
for the percentage of time animals spent in the open arms
(Figure 3a). Olanzapine also decreased the number of
entries into all arms of the EPM, with no significant
difference in effect between groups (Figure 3a). In the LDB,
a significant interaction between genotype and olanzapine
treatment in the time spent in the light compartment was
detected (Figure 3b). In the OFT, olanzapine decreased
activity and the number of entries into the center and
increased ACRs for both WT and En1þ /Otx2 mutants, with
no differential effect on genotypes (Supplementary
Figure 4). Overall, acute olanzapine treatment attenuated
manic-like behavior of mutants.
Figure 1 En1þ /Otx2 mutants show increased intra-individual fluctuations in spontaneous locomotor activity in their home cage. Animal activity for each
day was recorded for 30 days, normalized to the average activity level of that animal during the entire period, and shown as a function of day in separate
plots for each (a) WT and (b) En1þ /Otx2 mutant animal. (c) En1þ /Otx2 mutants showed increased intra-individual fluctuation as indicated by increased CV
(t13¼ 4.468, p¼ 0.001). Mutants showed (d) increased locomotor activity (GenotypeF1,44¼ 17.152, po0.001) with a significantly different profile of activity
(Genotype*HourF23¼ 5.674, po0.001). Two-tailed unpaired Student’s t-test: **po0.01.
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Chronic Lithium and Carbamazepine Treatments
Improve Abnormal Behavior of En1þ /Otx2 Mutants
To test the effects of mood-stabilizing drugs on En1þ /Otx2
mutants, we studied whether their behavioral alterations
can be reversed by the chronic treatment with lithium and
carbamazepine. The effect of lithium in the standard mouse
mania model, based on ampetamine-induced hyperlocomo-
tion, is strongly strain dependent (Gould et al, 2007). CD-1
mice were shown to not respond to lithium in this paradigm
(Gould et al, 2007). As all of the experiments described
above were performed on mutants maintained on a CD-1
genetic background, we investigated the effect of lithium on
these animals. En1þ /Otx2 mice on a CD-1 genetic back-
ground did not show response to chronic lithium treatment
with regard to their locomotor activity and risk-taking
parameters in the OFT experiments (data not shown).
The Black Swiss (BS) mouse strain responds to lithium in
the ampetamine-induced hyperlocomotion paradigm and
has been previously suggested to model aspects of mania
(Flaisher-Grinberg and Einat, 2010). Therefore, we back-
crossed En1þ /Otx2 mutants for six generations to a BS genetic
background and used these mice for the lithium and carbama-
zepine treatment experiments in the OFT (Figure 3c–n).
Behavioral fluctuations in the OFT were preserved in mutants
with this genetic background (Supplementary Figure 5).
Chronic lithium treatment in mutants significantly
reduced the percentage of the distance traveled in the
center (Figure 3e), while mutants did not exhibit signifi-
cantly decreased activity (Figure 3c) and frequency of
entries into the center of the OFT (Figure 3d). Treatment
with lithium selectively decreased the CV for the frequency
of entries into the center of the OFT (Figure 3g). There was
no interaction between genotype and treatment in CV for
locomotor activity (Figure 3f) or for the percentage of
distance traveled in the center (Figure 3h).
Carbamazepine selectively reduced locomotor activity,
frequency of entries, and percentage of distance traveled in
the center of the OFT in mutants (Figure 3i–k). The CV was
significantly reduced in mutants for locomotor activity
(Figure 3l), whereas a reduction was not observed for
frequency of entries and percentage of distance traveled in
the center of the OFT (Figure 3m and n). In summary,
chronic treatment with lithium and carbamazepine amelio-
rates aspects of altered behavior observed in mutants on the
BS genetic background.
Next we studied the effects of chronic carbamazepine
treatment on the fluctuations in mutants using the high
Figure 2 En1þ /Otx2 mutants show increased fluctuations in different behavioral paradigms. Individual animals are represented by different lines in the
separate graphs for mutants and controls. CV±SE was calculated and shown above x axis of the graph of both genotypes. Animal activity was recorded for
1 h in the OFT for six consecutive trials over 3 weeks (a–d). En1þ /Otx2 animals exhibited increased CV for (a) activity levels (t18¼ 3.029, p¼ 0.007), (b) the
percentage of entries into the center (t18¼ 2.482, p¼ 0.028), and (c) the percentage of the total distance they traveled in the center (t18¼ 2.864,
p¼ 0.014). CV for En1þ /Otx2 mutants was also increased for (d) ACRs (t18¼ 2.38, p¼ 0.027). In the social interaction test, animals of the same genotype
were recorded for 5min in four consecutive trials over 2 weeks. Fluctuation in the time animals interacted was calculated for four trials, following one initial
habituation trial. Mutants (e) showed an increased CV for the time they interacted (t16¼ 2.572, p¼ 0.020). Variance in sucrose preference was measured
during the course of 4 weeks. As quantified by an increase in the CV, more fluctuations were observed in mutants over time for (f) sucrose preference
(t18¼ 3.017, p¼ 0.007) and (g) sucrose intake (t18¼ 2.398, p¼ 0.028) but not for (h) total liquid intake (t18¼ 0.879, p¼ 0.391).
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temporal resolution provided by the telemetry data
acquisition system under the conditions used for the experi-
ment described in Figure 1 (home cage activity, constant
data recording, and animals on CD-1 genetic background).
Chronic carbamazepine treatment attenuated the fluctua-
tion in the activity of the mutants as demonstrated by a
Figure 3 Olanzapine, lithium, and carbamazepine improve behavioral parameters in En1þ /Otx2 mutants. Behavioral tests were conducted 1 h after IP
injection of vehicle or 1mg/kg olanzapine. In the EPM, (a) the increase in ratios of open arm vs total (open and closed arms) in mutants was reversed by
acute treatment with olanzapine (Genotype*TreatmentF1,36¼ 4.663, p¼ 0.038; Fisher’s LSD post hoc test, p¼ 0.022). There was no interaction between
genotype and treatment for the percentage of time animals spent in the open arms (Genotype*TreatmentF1,36¼ 0.251, p¼ 0.619). Number of entries to all arms
was decreased by olanzapine treatment (Genotype*TreatmentF1,36¼ 6.065, p¼ 0.019). This did not differ for WTs and mutants (Genotype*TreatmentF1,36¼ 0.335,
p¼ 0.566). In the LDB, a significant interaction between genotype and olanzapine treatment in (b) the time spent in the light compartment was detected
(Genotype*TreatmentF1,48¼ 5.666, p¼ 0.005). Animals were treated with lithium for 4 weeks before being exposed to six consecutive trials in the OFT over
3 weeks. Lithium did not significantly reduce (c) locomotor activity (Genotype*TreatmentF1,31¼ 0.005, p¼ 0.942) and (d) the number of entries into the center
of the OFT in mutants (Genotype*TreatmentF1,31¼ 1.794, p¼ 0.190), whereas for the distance traveled in the center (e), it resulted in a significant reduction
(Genotype*TreatmentF1,31¼ 4.291, p¼ 0.047; Fisher’s LSD post hoc test, p¼ 0.001). (f) Lithium treatment did not affect the CV for locomotor activity in mutants
(Genotype*TreatmentF1,31¼ 0.856, p¼ 0.362), while reducing it selectively for the frequency of entries into the center (g; Genotype*TreatmentF1,31¼ 6.544,
p¼ 0.016; Fisher’s LSD post hoc test, p¼ 0.032). There was no interaction between lithium treatment and genotype in CV for the distance traveled in the
center (h; Genotype*TreatmentF1,31¼ 0.001, p¼ 0.947). Animals were treated with carbamazepine for 2 weeks before being exposed to four consecutive trials
in the OFT over 2 weeks. Carbamazepine selectively reduced (i) locomotor activity (Genotype*TreatmentF1,35¼ 6.732, p¼ 0.014; Fisher’s LSD post hoc test,
p¼ 0.001); (j) frequency of entries (Genotype*TreatmentF1,35¼ 7.679, p¼ 0.009; Fisher’s LSD post hoc test, po0.001), and (k) distance traveled in the center
(Genotype*TreatmentF1,35¼ 4.696, p¼ 0.037; Fisher’s LSD post hoc test, p¼ 0.032) of the OFT in mutants. The CV was significantly reduced in mutants for their
locomotor activity (l; Genotype*TreatmentF1,35¼ 6.462, p¼ 0.016; Fisher’s LSD post hoc test, p¼ 0.012), whereas a reduction was not observed for (m)
frequency of entries (Genotype*TreatmentF1,35¼ 0.358, p¼ 0.553) and (n) distance traveled in the center of the OFT (Genotype*TreatmentF1,35¼ 0.021, p¼ 0.887).
Although exposed to carbamazepine, daily activity of animals was recorded for 21 days, normalized to the average activity of that animal, and shown as a
function in different color for each animal in separate plots for different groups. The CV±SE is calculated and shown for each group above x axis of the
graph representing that group. (o) Chronic carbamazepine treatment selectively reduced the elevated CVs of mutants (Genotype*TreatmentF1,16¼ 12.932,
p¼ 0.002; Fisher’s LSD post hoc test, p¼ 0.002), while the reduction of the hyperactivity in mutants did not reach statistical significance
(p; Genotype*TreatmentF1,16¼ 1.213, p¼ 0.287). Fisher’s LSD post hoc test: *po0.05, **po0.01, ***po0.001.
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specific reduction in CV for the activity in mutants over
time (Figure 3o), while the reduction in the hyperactivity in
mutants did not reach statistical significance (Figure 3p).
Serotonin Receptor Agonists Improve Behavioral
Alterations of En1þ /Otx2 Mutants
Next, we sought to study the mechanisms underlying the
altered behavior of En1þ /Otx2 mutants. Given the decreased
serotonin levels in En1þ /Otx2 mutants in all investigated
brain areas (Brodski et al, 2003; Tilleman et al, 2009), we
hypothesized that reduced serotonin has a critical role in
behavioral alterations of En1þ /Otx2 mutants.
Acute treatment with the mixed serotonin receptor
agonist quipazine selectively reduced the distance mutants
traveled in the OFT (Figure 4a). There was a significant
interaction between genotype and quipazine treatment in
the percentages of entries and time animals spent in the
open arms of the EPM (Figure 4b). Quipazine did not
significantly affect number of entries into all arms of the
apparatus (Figure 4b). On the basis of the receptor profile of
quipazine (Friedman et al, 1984) and the role of 5-HT2C
receptors in repressing DA activity (Di Matteo et al, 2000),
we hypothesized that the 5-HT2C receptor mediates the
quipazine effect. Indeed, the selective 5-HT2C agonist
CP-809101 reduced hyperactivity in En1þ /Otx2 mutants in
the OFT (Figure 4c). We conclude that the reduction of
serotonin receptor activation in En1þ /Otx2 mutants, speci-
fically of 5-HT2C receptors, is critically involved in the
hyperactivity and anxiety-like behavior observed in these
animals.
Sequence Variants in Genes Controlling the
Development of DA and 5-HT Neurons are Associated
with BPD
To study the relevance of our findings for BPD in humans,
we tested the hypothesis that variants in genes directing
specification of monoaminergic neurons are associated with
BPD. To this end, we employed INRICH, a pathway-based
genome-wide association analysis tool that tests for
enriched association signals of predefined gene sets across
independent genomic intervals (Lee et al, 2012).
Initially, we compiled two lists, containing genes control-
ling the specification of DA and 5-HT neurons, respectively.
Genes were included in the lists when a gain- or loss-of-
function mutation in mammals leads to a change in the
specification of midbrain DA or rostral hindbrain 5-HT
neurons in vivo (see Supplementary Methods for further
details). Using INRICH, both DA and 5-HT specification
pathways showed a significant global enrichment for BPD.
For the DA pathway, 10 out of 34 genes were in associated
intervals and for the 5 HT pathway 4 out of 19 genes
(Table 1).
Recently, a list compiling all mouse mutants showing
alterations in the development of DA neurons has been
reported (Hegarty et al, 2013). To further validate our
findings, we used the list of genes mutated in these animals
for INRICH analysis. We found that genes controlling the
specification of DA neurons showed significant global
enrichment (Table 1). In contrast, the global enrichment
for all genes affecting DA development, including migration
and projection, did not show significant association
(p¼ 0.177). Global enrichment values stayed significant
after FDR correction for multiple testing for our compiled
DA specification list and for the lists based on the
publication by Hegarty et al (Table 1).
Finally, we tested genes directing the specification of DA
and 5-HT neurons to determine if they are associated with
schizophrenia and major depressive disorder. Global enri-
chment with these disorders was not observed (Table 1).
Taken together, our findings indicate that common DNA
variants within genes controlling the specification of DA
and 5-HT neurons are associated with BPD in humans.
DISCUSSION
In the present study, we report that mutants exhibiting
alterations in the specification of monoaminergic neurons
show endogenous fluctuations of manic- and depressive-
like behaviors. Drugs used for the treatment of BPD, as well
as serotonin receptor agonists, ameliorate the behavioral
alterations in these animals. In addition, we provide
evidence that a linkage disequilibrium-independent geno-
mic enrichment analysis yields an association of BPD with
aggregates of genes directing the specification of mono-
aminergic neurons. In summary, our data indicate that
aberrations in the genetic pathways regulating specification
of DA and 5-HT neurons lead to mood instability.
Figure 4 Quipazine and CP-809101 reduce hyperactivity of En1þ /Otx2 mutants in the open field. Animals were tested 15min after IP injection of saline,
5mg/kg quipazine, or 5mg/kg CP-809101. (a) Quipazine specifically decreased distance traveled in the OFT for mutants (Genotype*TreatmentF1,36¼ 8.429,
p¼ 0.006; Fisher’s LSD post hoc test, p¼ 0.001). (b) There was a significant interaction between genotype and quipazine treatment in percentages of entries
into (Genotype*TreatmentF1,36¼ 11.534, p¼ 0.002) and the time spent in the open arms of the EPM (Genotype*TreatmentF1,36¼ 9.286, p¼ 0.005), with no such
interaction in the number of entries into all arms (Genotype*TreatmentF1,36¼ 1.352, p¼ 0.254). (c) The selective 5-HT2C agonist CP-809101 reduced
hyperactivity in En1þ /Otx2 mutants in the OFT (Genotype*TreatmentF1,36¼ 4.249, p¼ 0.047; Fisher’s LSD post hoc test, po0.001). Fisher’s LSD post hoc test:
*po0.05, **po0.01, ***po0.001.
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Our results further suggest that genetic variants in these
pathways are associated with BPD in humans.
Validity and Limitations of En1þ /Otx2 Mutants as Model
for Mood Fluctuations and BPD
The molecular underpinnings of spontaneous mood fluc-
tuations are virtually unknown, in large part due to the lack
of suitable animal models. We now propose En1þ /Otx2
mutants as a model for this behavior and offer evidence that
it can be caused by a neurodevelopmental aberration.
Behavioral fluctuations observed in BPD are challenging to
model in animals, and current paradigms emulate limited
aspects of this disorder (Chen et al, 2010; Gould and Einat,
2007; Kara and Einat, 2013; Nestler and Hyman, 2010).
Although En1þ /Otx2 mutants do not mimic all aspects of
BPD, they represent a significant advancement toward more
valid BPD models. In the following, we discuss validity and
limitations of En1þ /Otx2 mutants as a BPD model.
Face validity. Mutants show manic- and depressive-like
behavior. The former as indicated by increased locomotor
activity and risk-taking behavior, and the latter as indicated
by the reduced hedonic-like behavior. Significantly, mu-
tants show also increased fluctuations in these behaviors.
For the interpretation of the results, it is important to
address whether increased variability could be confounded
by differences in the absolute measures. Different results
suggest that this is not the case. For both mutants and
controls, the levels of locomotor activity are not correlated
with the levels of fluctuations in the open field. Moreover,
mutants and controls do not differ in the distance traveled
in the center of the OFT, whereas the fluctuation in these
parameters is increased in mutants. Finally, in the phar-
macological experiments, changes in the fluctuations for the
distance animals traveled in the center and the frequency
animals entered the center did not correlate with changes in
the absolute measures.
Mutants showed fluctuations in both manic- and
depressive-like behavior, recapitulating aspects of a mixed
state in BPD patients, defined by co-occurrence of manic
and depressive symptoms (McElroy et al, 1995; Perugi et al,
2013). However, most of the mutants did not switch
between manic- and depressive-like symptoms over time.
One possible explanation for the low number of mutants
switching between manic- and depressive-like states in the
Table 1 Association between Polymorphisms of the Genes Specifying DA and 5-HT Neurons and Psychiatric Disorders
Gene List Number of
genes
Pval. BPD Pval. SCZ Pval. MDD
Dopaminergic specification
BDNF (Baquet et al, 2005), CDH2 (Sakane and Miyamoto, 2013), CTNNB1 (Tang et al, 2010), DKK1
(Ribeiro et al, 2011), EGFR (Iwakura et al, 2011), EN1 (Alberi et al, 2004; Alves dos Santos and Smidt,
2011; Ellisor et al, 2012; Simon et al, 2001), EN2 (Ellisor et al, 2012; Simon et al, 2001), FERD3L (Ono
et al, 2010), FGF2 (Ratzka et al, 2012), FGFR1 (Lahti et al, 2012), FGFR2 (Lahti et al, 2012), FOXA1
(Ferri et al, 2007), FOXA2 (Ferri et al, 2007; Hynes et al, 1995), GDNF (Kholodilov et al, 2004), GLI1
(Hynes et al, 1997), GLI2 (Matise et al, 1998a), LMX1A (Andersson et al, 2006b; Deng et al, 2011),
LMX1B (Deng et al, 2011; Smidt et al, 2000), MSX1 (Andersson et al, 2006b), NEUROG2 (Andersson
et al, 2006a; Kele et al, 2006), NR4A2 (Zetterstrom et al, 1997), ONECUT1 (Chakrabarty et al, 2012),
ONECUT2 (Chakrabarty et al, 2012), OTX2 (Brodski et al, 2003; Omodei et al, 2008), PHOX2B (Deng
et al, 2011; Hoekstra et al, 2012), PITX3 (Smidt et al, 2004), RSPO1 (Hoekstra et al, 2013), SHH
(Joksimovic et al, 2009), SMO (Hynes et al, 2000a), TGFA (Blum, 1998), UNCX (Rabe et al, 2012),
WNT1 (Alves dos Santos and Smidt, 2011; Ellisor et al, 2012; Prakash et al, 2006), WNT2 (Sousa et al,




Dopaminergic specification (Hegarty et al, 2013)
CTNNB1, DKK1, EN1, EN2, FERD3L, FGF2, FGFR1, FOXA2, FZD3, FZD6, GLI1, GLI2, HES1, LMX1A,






ASCL1 (Pattyn et al, 2004), EN1 (Fox and Deneris, 2012; Simon et al, 2005), EN2 (Fox and Deneris,
2012), FOXA2 (Jacob et al, 2007), GATA2 (Craven et al, 2004), GATA3 (van Doorninck et al, 1999),
GLI1 (Hynes et al, 1997), GLI2 (Matise et al, 1998b), INSM1 (Jacob et al, 2009), LMX1B (Ding et al,
2003), STXBP1 (Dudok et al, 2011), NKX2-2 (Briscoe et al, 1999), OTX2 (Brodski et al, 2003), FEV
(Hendricks et al, 2003), PHOX2B (Pattyn et al, 2003), SIM1 (Osterberg et al, 2011), SHH (Hynes et al,
1997), SMO (Hynes et al, 2000b), WNT1 (Simon et al, 2005)
19 0.028 1 1
aFDR corrected p-values; Abbreviations: MDD, major depressive disorder; SCZ, schizophrenia. For the references see the supplement.
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tests we used is that the time period during which we
observed the animals was too short to detect a potential
switch. Another possible explanation regards the experi-
mental design of the sucrose preference test. In this
paradigm, En1þ /Otx2 mutants demonstrated a reduced
sucrose preference. Some mutants, however, achieved the
maximal sucrose preference, that is, 100%, as did most of
the WT mice. Because the test does not allow assessment of
sucrose preferences above the WT levels, this ‘ceiling effect’
might mask periods during which mutants switch to
increased hedonic-like behavior.
In contrast to BPD patients, En1þ /Otx2 mutants show
changes in their inferior colliculi and cerebellar vermis
leading to ataxia, not correlated to their hyperactivity
(Broccoli et al, 1999; Brodski et al, 2003). Although the
cerebellum has been associated with manic- and depressive-
like behavior (Baldacara et al, 2011; Supple et al, 1988), our
pharmacological experiments suggest that the behavioral
alterations of En1þ /Otx2 mutants are primarily caused by
dysfunctions in monoaminergic neurotransmission.
Predictive validity. Drugs used for the treatment of BPD
ameliorate behavioral alterations of En1þ /Otx2 mutants.
Although lithium only partially improved the En1þ /Otx2
phenotype, carbamazepine reversed most of the behavioral
parameters observed in mutants, importantly also including
hyperactivity and fluctuations in locomotor activity.
Lithium has been estimated to be less effective in atypical
forms of BPD, such as mixed manic state, whereas
anticonvulsant mood stabilizers appear to cover a broader
spectrum of BPD (Fountoulakis et al, 2012; Swann et al,
1997). This suggests that the predictive validity of En1þ /Otx2
mutants is higher for atypical forms of BPD.
Construct validity. The INRICH analysis suggests an
abnormal specification of both DA and 5-HT neurons in
BPD. En1þ /Otx2 mutants are particularly well suited to
recapitulate these changes. First, the underlying mutation
affects the specification of these neurons and not their
migration or projection. Second, the mutation affects both
transmitter populations.
Pathway Enrichment Analysis for GWAS in BPD
Many genes included in the lists compiled for the INRICH
study have previously been implicated in BPD, including
members of the Wnt pathway, Fgf pathway, BDNF, and
EGFR (Pandey et al, 2012; Pedroso et al, 2012; Post, 2007;
Sklar et al, 2008; Turner et al, 2012). Our results suggest that
these genes, which serve very different biological functions
and have not previously been attributed to a common
pathway, are associated with BPD by way of their effect on
the formation of monoaminergic neurons.
In addition, susceptibility genes for BPD, for example,
Odz4, which have so far not been implicated in the genera-
tion of monoaminergic neurons, might be required for this
process (Psychiatric GWAS Consortium Bipolar Disorder
Working Group, 2011). Indeed, during mouse embryogen-
esis, expression of Odz4 strongly overlaps with Otx2 and
Wnt1. In Drosophila, moreover, its ortholog regulates the
expression of theWnt1 ortholog (Zhou et al, 2003). It would
be useful therefore to determine whether Odz4 has a role in
the formation of monoaminergic neurons.
Molecular Mechanisms Underlying Fluctuations in
Manic- and Depressive-Like Behavior in En1þ /Otx2
Mutants
A mixed manic state, similar to the one observed in
En1þ /Otx2 mutants, has been described in mice in which the
Clock gene has been reduced by shRNA, specifically in the
ventral tegmental area (Mukherjee et al, 2010). Microarray
experiments found hundreds of genes upregulated in this
brain region, including Otx2 (Mukherjee et al, 2010). As the
En1 and Otx2 promoters are active in adult DA neurons, it
cannot be excluded that the overexpression of Otx2 in adult
neurons of mutants contributes to the behavioral phenotype
of these animals. However, as the changes in monoaminergic
neurons in mutants originate during embryogenesis and
persist throughout adulthood, it strongly suggests that
behavioral alterations in these animals result from develop-
mental disruptions.
Our finding that the serotonin receptor agonist quipazine
reverses hyperactivity in En1þ /Otx2 mutants supports the
conclusion that reduction of 5-HT neurotransmission has a
key role in the hyperactivity of these animals. Quipazine
predominantly binds to 5-HT2 and 5-HT3 receptors (Roth
and Hyde, 2000), suggesting that they mediate the effect of
quipazine on En1þ /Otx2 mutants. The reduction of hyper-
activity of En1þ /Otx2 mutants by the specific 5-HT2C
receptor agonist CP-809101 indicates that this receptor
subtype has a critical role in the phenotype of En1þ /Otx2
mutants. This is in accordance with previous findings
indicating antipsychotic activity of CP-809101 and identify-
ing 5-HT2C receptors as a potential drug target for BPD
(Siuciak et al, 2007).
It is known that DA neurons have a predominantly
excitatory effect on 5-HT neurons, whereas 5-HT neurons
have a mostly inhibitory effect on DA neurons (Di Giovanni
et al, 2008; Guiard et al, 2008). On the basis of lesion
studies, it could be expected that the loss of 5-HT neurons
in En1þ /Otx2 mutants would lead to increased firing activity
of VTA DA neurons (Guiard et al, 2008). The increased
DA activity would then activate remaining 5-HT neurons
(Di Giovanni et al, 2008), which would in turn increase their
inhibitory effect on DA neurons. Further study of this
monoaminergic transmission balance in En1þ /Otx2 mutants
is expected to reveal how such feedback loops, intended to
regulate monoaminergic homeostasis, underlie behavioral
fluctuations observed in En1þ /Otx2 mutants.
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